The main goal of our project was to decipher the molecular events leading to VOC in order to develop new therapies.

Studies were performed in Paris and in Pointe-à-Pitre and benefited from cohorts of SCD patients that were constituted thanks to our strong collaboration with clinicians in Ile de France (Necker, European Georges Pompidou, Robert Debré hospitals) and in Guadeloupe (CHU Pointe à Pitre).

We investigate the role of RBCs in vaso-occlusion and thrombotic events in hematological and non-hematological human diseases including Polycythemia Vera (PV), Gaucher disease (GD) and Central Retinal Vein Occlusion (CRVO).

All these pathologies have ischemic phenomena that remain unexplained.

The red cell plasma membrane contains integral membrane proteins allowing the diffusion of molecules between the plasma and the RBCs. A fine regulation of these exchanges is crucial for maintaining homeostasis of the intracellular pH (pHi) and the water content in response to physiological variations, and plays a major role in membrane mechanical properties and membrane biogenesis. We aim to full understand the mecanisms involved in the expression and function of RBC transporters and channels whose dysfunctions are involved in many red cell pathologies

The aims of this group are to insure immunological security of RBC transfusion, notably in patients with a rare erythrocyte phenotype, by resolving complex immune-hematological issues.

During the past years, the French National Immunohematology Reference Laboratory (CNRGS) contributed to the implementation of new serological and molecular diagnostic techniques for a better characterization of blood group systems.